| 000 | 01604 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250518024321.0 | ||
| 264 | 0 | _c20190425 | |
| 008 | 201904s 0 0 eng d | ||
| 022 | _a1432-0584 | ||
| 024 | 7 |
_a10.1007/s00277-019-03633-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDulucq, Stephanie | |
| 245 | 0 | 0 |
_aImpact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line. _h[electronic resource] |
| 260 |
_bAnnals of hematology _cMay 2019 |
||
| 300 |
_a1159-1168 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImatinib Mesylate _xadministration & dosage |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aRNA, Messenger _xgenetics |
| 650 | 0 | 4 |
_aRNA, Neoplasm _xgenetics |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aEtienne, Gabriel | |
| 700 | 1 | _aMorisset, Stephane | |
| 700 | 1 | _aKlein, Emilie | |
| 700 | 1 | _aChollet, Claudine | |
| 700 | 1 | _aRobbesyn, Fanny | |
| 700 | 1 | _aTurcq, Beatrice | |
| 700 | 1 | _aTigaud, Isabelle | |
| 700 | 1 | _aHayette, Sandrine | |
| 700 | 1 | _aNicolini, Franck E | |
| 700 | 1 | _aMahon, François-Xavier | |
| 773 | 0 |
_tAnnals of hematology _gvol. 98 _gno. 5 _gp. 1159-1168 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00277-019-03633-x _zAvailable from publisher's website |
| 999 |
_c29406156 _d29406156 |
||